Skip to Main Content

Imaging SV2A in mood disorders

  • Study HIC#:1511016789
  • Last Updated:03/12/2020

The goal of the study is to determine whether there are alterations in synaptic vesicle glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A density at time of its greatest anti-depressant response. We will conduct an examination of SV2A and associated consequences using neuroreceptor imaging and behavioral techniques.

  • Age18 years - 70 years
  • GenderBoth
  • Start Date03/18/2016
  • End Date03/14/2022

Trial Purpose and Description

The goal of the study is to determine whether there are alterations in synaptic vesicle glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A density at time of its greatest anti-depressant response. We will conduct an examination of SV2A and associated consequences using neuroreceptor imaging and behavioral techniques.

Eligibility Criteria

Inclusion Criteria:

Medically healthy individuals, ages 18-70, with a diagnosis of major depressive disorder (MDD), bipolar disorder, or Post-Traumatic Stress Disorder (PTSD).  We also accept healthy controls.

Principal Investigator

Sub-Investigators

For more information about this study, contact:

Or contact the Help us Discover team on: